Abstract The therapeutic use of T cell receptor (TCR)-transduced peripheral blood lymphocytes (PBL) targeting tumor-associated antigens is emerging as a promising investigational treatment for patients with cancer. Initial response rates to therapy were low, suggesting the need to improve the function of TCR-transduced PBL. We constructed standard bicistronic retroviral vectors using an internal promoter or internal ribosomal entry site element as well as vectors incorporating coding sequences for 2A linker peptides between coding sequences for and chains targeting the cancer-testis (CT) antigen, NY-ESO-1. Incorporation of coding sequences for 2A linker peptides in the bicistronic TCR expression cassette resulted in up to a fourfold increase in TCR expression and a signiWcant improvement in eVector function as measured by interferon-gamma release following co-culture with peptidepulsed targets and NY-ESO-1+ tumors. We also sought to enhance reactivity of TCR-transduced PBL against tumor targets by modulation of tumor antigen expression on target cells. Induction of NY-ESO-1 expression on tumor targets using the demethylating agent 5-aza-2Ј-deoxycytidine (alone or in combination with the histone deacetylase inhibitor depsipeptide) resulted in enhanced interferon-gamma secretion by the TCR-transduced PBL on culture with treated targets. Taken together, these results indicate that design of TCR-based vectors incorporating 2A linker peptides improves TCR expression and eVector function of transduced PBL. Furthermore, induction of CT antigen expression through treatment of tumor targets with chromatin-remodeling agents may augment TCR-based immunotherapy targeting these antigens. These results have relevance for TCR-based gene therapies targeting common epithelial malignancies.
Introduction
Immunotherapy involving the transfer of genes encoding T cell receptors (TCRs) into peripheral blood lymphocytes (PBL) is based on the foundation of knowledge gained from the study of tumor-inWltrating lymphocytes (TIL). Fundamental advances have been made in the past two decades with regard to adoptive transfer of TIL, resulting in response rates exceeding 50% when autologous reactive TIL were transferred following a lymphodepleting conditioning regimen [1] . Despite these advances, several limitations of this technology exist. This therapy requires a surgical procedure to procure TIL, and mandates that tumor-reactive cells be isolated and expanded ex vivo, which limits the application of this therapy to one-half of eligible patients with metastatic melanoma.
To overcome these limitations, approaches to cancer immunotherapy have been developed based on the genetic modiWcation of normal PBL. We successfully cloned TCRs against several tumor-associated antigens (TAA) found in melanoma, including MART-1 and gp100 [2, 3] . Retroviral vectors incorporating these cloned TCR were used to transduce PBL, resulting in the generation of cells capable of recognizing and destroying both fresh and cultured melanoma cells in vitro [2, 4] . Based on these observations, 15 patients with metastatic melanoma were treated with genetically engineered lymphocytes transduced to express a TCR targeted at MART-1, and durable engraftment at levels exceeding 10% of PBL was observed for at least 2 months [3] . Two of the 15 patients demonstrated high sustained levels of circulating cells at 1 year following infusion, which was associated with objective regression of metastatic lesions [3] .
In an eVort to extend the scope of immunotherapy toward diverse cancer histologies, we cloned a TCR targeting NY-ESO-1 [5] , a cancer-testis (CT) antigen frequently expressed in melanoma as well as a wide range of non-melanoma epithelial malignancies [6, 7] . CT antigens are proteins encoded by genes that are normally expressed only in germ cell tissues, trophoblasts, and certain tumors but not in normal tissues [6, 7] . There has been growing interest in the use of CT antigens as targets for immunotherapy.
NY-ESO-1 was originally discovered by screening the serum of a patient with esophageal cancer using 'serological identiWcation of antigens by recombinant expression cloning' [8] . Since that time, its expression has been described in a variety of common tumors (20-80% at the RNA level), including melanoma and cancers of the breast, lung, bladder, liver, prostate, and ovary [6] . Of note, some of these cancer patients develop antibody responses to NY-ESO-1 [6] . NY-ESO-1 is one of the most immunogenic of the CT antigens, and has been a target for immunotherapy in multiple clinical trials [9] [10] [11] [12] . NY-ESO-1 oVers a potential advantage as a target for TCR-based gene therapy as its expression is limited to neoplastic cells and germ line tissues, thus the risk for autoimmune complications is low. This is in contrast to the melanoma diVerentiation antigens such as MART-1 and gp100, which are expressed in normal tissues as well as in tumors.
We generated a retroviral vector encoding DNA for TCR genes targeting the HLA-A2-restricted epitope the NY-ESO-1 antigen [5] , and demonstrated that T cells engineered with this vector recognize multiple cancer histologies. The original vector design for the NY-ESO-1 TCR vector employed an internal promoter, phosphoglycerate kinase (PGK), to drive expression of the second of the TCR genes (the chain, in this case). However, use of an internal promoter in retroviral vectors can lead to substantially lower expression of the second gene [13] . Recently, a mechanism to improve expression in multi-cistronic constructs was described utilizing 2A linker peptides [14, 15] . These peptide sequences are derived from viruses such as the porcine teschovirus, foot-and-mouth disease virus, and Thosea asigna virus [16] [17] [18] . 2A peptides contain a consensus motif that utilizes a ribosomal skip mechanism to inhibit peptide bond formation between adjacent protein coding sequences. As a result, use of these 2A peptides to link sequences encoding several proteins in the same open reading frame results in near-complete separation and stoichiometric production of the encoded proteins [14] . This technique has been used in other model systems including the production of monoclonal antibodies [15] . We thus incorporated these 2A linker peptides in construction of retroviral vectors targeting the class I-restricted epitope of the CT antigen, NY-ESO-1.
One potential advantage in targeting CT antigens such as NY-ESO-1 is that the expression of these antigens can be up-regulated in tumor cells [19] . We have previously reported that treatment with the demethylating agent 5-aza-2Ј-deoxycytidine (DAC) can induce expression of NY-ESO-1 in melanoma and non-melanoma cell lines [20] . We have now employed this approach in an eVort to sensitize tumor targets to PBL transduced with a TCR targeting the NY-ESO-1 antigen, and report the Wndings herein.
This report presents the results of studies indicating that the use of 2A linker peptides in retroviral vectors containing bicistronic TCR expression cassettes leads to signiWcantly improved expression and enhanced eVector function of TCR-transduced PBL. This vector design has signiWcant implications for TCR-based therapies targeting melanoma as well as non-melanoma epithelial malignancies. In addition, induction of NY-ESO-1 antigen expression in patients may provide a useful adjunct to adoptive cell transfer in the treatment of malignancy.
Materials and methods

Patient PBL and cell lines
All of the PBL used in this study were from metastatic melanoma patients treated at the Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, MD, USA. T2 is a lymphoblastoid cell line deWcient in TAP function, whose HLA class I proteins can be easily loaded with exogenous peptides [21] . Melanoma lines 1300mel (NY-ESO-1+, HLA-A2+), 624.38mel (NY-ESO-1+, HLA-A2+), 888mel (NY-ESO-1¡, HLA-A2¡), 526mel (NY-ESO-1¡, HLA-A2+), A375 (NY-ESO+, HLA-A2+), and SK23 (NY-ESO¡, HLA-A2+) were generated at the Surgery Branch from resected tumor lesions, as previous described [22] . The H2373 pleural mesothelioma cell line (NY-ESO-1¡, HLA-A2+), BE-3 esophageal cancer cell line, and H1299 non-small cell lung carcinoma cell line (NY-ESO-1+, HLA-A2¡) were kindly provided by Dr David Schrump, National Institutes of Health. The H1299 small cell lung carcinoma line was transduced with retroviral construct to express HLA-A*0201 as previously described [23] , and was designated H1299-A2. Cells obtained from other sources include: PG13 gibbon ape leukemia virus-packaging cell line (ATCC CRL 10-686), the human lymphoid cell line SupT1 (ATCC CRL-1942), the human pancreatic cancer cell line Panc-1 (ATCC CRL-1469) (NY-ESO-1¡, HLA-A2+), the human glioblastoma cell line LNZTA3WT4 (ATCC CRL-11543) (NY-ESO-1¡, HLA-A2+), the human ovarian cancer cell line OVCAR-3 (ATCC HTB-161) (NY-ESO-1¡, HLA-A2+) and the human ecotropic packaging cell line, Phoenix Eco (kindly provided by G. Nolan, Stanford University, Stanford, CA, USA). All the cell lines described above were maintained in R10 [RPMI 1640 (Invitrogen, Inc. Rockville, MD, USA) supplemented with 10% FCS (BioXuid, Inc., Gaithersburg, MD, USA)]. Culture medium (CM) for T lymphocytes was AIM V (Invitrogen), 300 IU/ml IL-2 (Chiron Corp., Emeryville, CA, USA), plus 5% human AB serum (Valley Biomedical, Winchester, VA, USA).
Peptide synthesis
Synthetic peptides used in this study were made using a solid phase method on a peptide synthesizer (Gilson Co. Inc., Worthington, OH, USA) at the Surgery Branch of the NCI. The quality of each peptide was evaluated by mass spectrometry (Biosynthesis Inc., Lewisville, TX, USA). The sequences of the peptide used in this study are as follows: NY-ESO-1 p157-165 (SLLMWITQC), gp100 209-217 [3] , Mart-1 27-35 [2] .
Cysteine-modiWed TCR generation and cloning
We generated cysteine-modiWed and chains using a polymerase chain reaction (PCR) megaprimer approach. The Wrst fragment was generated by amplifying the chains with a 5Ј-speciWc primer and either the -Cys48rev primer, TAGACCTCATGTCTAGCACGCATTTGTCTGTGATA TACACATC or the -Cys57rev primer, TGAGGGGCTGC GGGTCCGTGCAGACCCCACTGTGCACCTCC for the and chains, respectively (mutated bases are underlined). The product of this reaction was then used as a megaprimer to amplify full-length TCR chain with a 3Ј-speciWc primer. The full-length chain was subcloned into pGEM vector as previously described [23] .
Construction of retroviral vectors
The retroviral vector backbone used in this study, pMSGV1, is a derivative of the vector pMSGV [murine stem cell virus (MSCV)-based splice-gag vector] which utilizes a MSCV long terminal repeat (LTR) [5] . Five vectors were constructed using PCR of four DNA fragments: pMSGV1 (NcoI/NotI), NY-ESO-1 TCR chain (NcoI/ Production of retroviral supernatant from stable producer cell clones
Generation of PG13-packaging cell clones was initiated by
Wrst transfecting Phoenix Eco cells with 4 g of DNA for each construct using the Lipofectamine reagent (Invitrogen). PG13 cells were then transduced with supernatant from Phoenix Eco cells, and PG13 cell clones were obtained by limiting dilution. Clones were expanded, and high titer clones were selected by the dot-blot titration method [24] . Clones were determined to be producing biologically active retroviral vector by transduction of SupT1 cells and analysis of FACS data (using anti-CD3 and NY-ESO-1 tetramer). MSGIN, whose name is derived from MSCV-based splice vector green Xuorescent protein (GFP)-internal ribosomal entry site (IRES)-neo, was used as a control vector that expresses GFP.
Transduction of PBL
Peripheral blood lymphocytes were collected by leukapheresis and lymphocytes were resuspended at a concentration of 1 £ 10 6 /ml in media supplemented with OKT3 (50 mg/ ml) and IL-2 (300 IU/ml). Lymphocytes were plated at 1 £ 10 6 /ml in 24-well plates (Costar), and were cultured for 48 h prior to transduction. Lymphocytes were transduced with retroviral vectors by centrifugation (2,000g) with retroviral supernatant and protamine sulfate (10 g/ml).
Flow cytometry analysis
Cell surface expression of CD3, CD4, CD8 (BD Biosciences), V 13.1 (Immunotech), and NY-ESO-1 tetramer (Beckman Coulter) on PBL was measured by immunoXuorescence using FITC, PE, PE-Cy7, or APC. HLA class I expression in cultured cancer cells was evaluated by Xow cytometric techniques using the W6/32 antibody (Sera-Lab, Sussex, UK) that recognizes only functional class I molecules. For analysis, the relative log Xuorescence of live cells was measured using a FACScan Xow cytometer (BD Biosciences).
Cytokine release assays
Peripheral blood lymphocyte cultures were tested for reactivity in cytokine release assays using commercially available ELISA kits (IFN-; Endogen, Cambridge, MA, USA). T2 cells were pulsed with peptide (1 g/ml, or as described in Wgures) in CM for 3 h at 37°C, followed by washing (three times) prior to incubation of co-cultures. For these assays, 1 £ 10 5 eVector cells (PBL) and 1 £ 10 5 stimulator cells (T2 cells or tumor cells) were incubated in 0.2 ml culture volume in individual wells of 96-well plates. EVector cells and responder cells were co-cultured for 24 h. Cytokine secretion (interferon-gamma) was measured in culture supernatants diluted so as to be in the linear range of the assay.
DAC-DP Exposure 5-Aza-2Ј-deoxycytidine was purchased from Sigma Chemical (St Louis, MO, USA). The Developmental Therapeutics Program at the NCI provided depsipeptide (DP). Following optimization of the kinetics of gene induction in preliminary experiments, the eVects of DAC, DP, or sequential DAC-DP treatment on NY-ESO-1 expression was determined after exposure to (1) normal media (NM) for 96 h; (2) 0.1 mol/l DAC for 72 h, followed by NM for 24 h; (3) NM for 72 h, then 25 ng/ml DP for 6 h, followed by NM for 18 h; or (4) sequential DAC-DP, followed by NM for 18 h. For each experiment, day 0 represented the time when cells were initially exposed to either NM or DAC. During the treatment regimen, media were changed every day, and after appropriate drug exposure, cells were washed with Hanks balanced salt solution. Quantitative reverse-transcriptase PCR (RT-PCR) and gel PCR were performed at the 96-h time point.
RNA extraction and real-time quantitative reversetranscriptase-polymerase chain reaction analysis Total RNA was isolated from cell lines using reagents and protocols provided in the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Synthesis of cDNA was performed with 2 g total RNA using a reverse transcription kit (Promega, Madison, WI, USA) and oligo (dT) 15 primers. Quantitative RT-PCR (TaqMan) analysis of gene expression was performed in a blinded manner using an ABI prism 7700 Sequence Detection System (Perkin-Elmer, Foster City, CA, USA) [25, 26] . TaqMan probes [labeled at the 5Ј end with the reporter dye molecule FAM (6-carboxyXuorescein) and at the 3Ј end with the quencher dye TAMRA (6-carboxytetramethylrhodamine)] were purchased from PE Biosystems Oligonucleotide Factory (Foster City, CA, USA). NY-ESO-1, -actin, and GAPDH primer sequences and methods for quantitative RT-PCR analysis, including generation of cDNA standards, and thermal cycling parameters have been described [27, 28] . cDNA from 586mel was used to generate the relative standard curves for NY-ESO-1, -actin, and GAPDH. Samples were standardized by dividing the copy number of the target gene by that of the endogenous reference gene ( -actin or GAPDH).
Results
TCR expression of transduced PBL
Using the anti-NY-ESO-1 TCR previously described [29] , Wve retroviral vectors, MSGV1-1G4-APB (APB), MSGV1-1G4-AIB (AIB), MSGV1-1G4-AGSGP2AB (GSGP2A), MSGV1-1G4-AGSGT2AB (GSGT2A), and MSGV1-1G4-AT2AB (T2A), were initially constructed. The APB construct used the retroviral MSCV LTR to drive the expression of chain with the chain governed by an internal PGK promoter, while the AIB construct incorporated an IRES between coding sequences for the and chains of the TCR (Fig. 1) . The remaining three retroviral constructs, GSGP2A, GSGT2A, and T2A used the retroviral MSCV LTR to drive expression of the of and chains as a single open reading frame with the incorporation of 2A linker peptides (Fig. 1) .
To assess vector function prior to generation and cloning of stable producer cell clones, anti-NY-ESO-1 TCR vectors were produced by transient transfection as described (see Sect. 'Materials and methods'). Lymphocytes were transduced on day 2 post-stimulation with supernatant from these cultures. Five days following transduction, cells were harvested and stained for CD8, and NY-ESO-1 tetramer. Representative PBL transductions for the APB, AIB, GSGP2A, GSGT2A, and T2A vectors were as shown in Fig. 2 . Transduction with constructs incorporating 2A peptides resulted in signiWcantly higher expression of the TCR measured by staining with the NY-ESO-1 tetramer (Fig. 2a) . No appreciable staining of NY-ESO-1 tetramer was noted following transduction with supernatant from the IRES construct, thus this construct was not pursued further.
Stable producer cell lines for the APB, GSGP2A, GSGT2A, and T2A constructs were generated as previ-ously described (see Sect. 'Materials and methods'). Six packaging cell clones from each construct with the highest physical titer were used to transduce the human T cell line SupT1, and CD3 expression was assayed by FACS analysis (Supplementary Table 1 ). SupT1 is defective in endogenous TCR chain biosynthesis and will not mobilize the CD3 protein complex to the cell surface unless supplied with a substitute chain. CD3 expression ranged from 6 to 96%. Clones APB 38, GSGP2A 3, GSGT2A 36, and T2A 24 exhibited both high physical titer and high transduction eYciency, and these four constructs were chosen for additional study (Supplementary Table 1) .
To test the hypothesis that use of 2A linker peptides would result in improved TCR expression, PBL were transduced with each of the anti-NY-ESO-1 TCR vector constructs on day 2 post-stimulation. Five days following transduction, cells were harvested and stained for V 13.1, and NY-ESO-1 tetramer. Examples of transductions using the high tier producer clones of APB, GSGP2A, GSGT2A, and T2A were as shown in Fig. 2b . Transduction with constructs incorporating 2A peptides resulted in signiWcantly higher expression of the TCR, both by V 13.1 staining and NY-ESO-1 tetramer (Fig. 2b) . These Wndings were consistent in four independent experiments. There was little variability in TCR expression following transduction of PBL with each of the 2A constructs, yielding equivalent expression and signiWcantly higher TCR expression when compared to the PGK promoter-containing vector.
Functional studies of the transduced PBL To determine whether the increased TCR expression in the 2A constructs was associated with increased release of eVector cytokines by TCR-transduced PBL, lymphocytes were transduced with supernatants from the top producer clone for each of the constructs. The transduced PBL were then co-cultured with T2 cells pulsed with cognate (NY-ESO-1) or irrelevant inXuenza peptide. Antigen-speciWc IFN-release was detected in co-cultures of peptide-pulsed T2 cells for all constructs, with a higher level of cytokine secretion for PBL transduced with the constructs incorporating the 2A linker peptides (Fig. 3a) . These Wndings were consistent in four independent experiments. NY-ESO-1 is expressed in a wide range of malignancies, and in over a third of melanoma tumors [11] . We have previously shown that PBL transduced with our original TCR vectors targeting the NY-ESO-1 antigen are able to secrete IFN-and lyse HLA-A2+, NY-ESO-1+ melanoma targets in an antigen-speciWc manner [5] . To determine whether the increased eVector cytokine production of PBL transduced with the 2A constructs with peptide-pulse T2 cells trans- Fig. 1 Design of NY-ESO-1 TCR retroviral vectors. Schematic representation of six retroviral vectors used to transfer and express the TCR genes targeting the HLA-A2-restricted immundominant epitope of NY-ESO-1. Vector MSGV1-1G4-AIB is a bicistronic vector design where the LTR promoter drives the expression of both TCR and genes linked by an IRES. In vector MSGV1-1G4-APB (APB), the expression of the chain is mediated by the vector LTR gene promoter, whereas chain expression is driven by an internal PGK promoter. In each of the vectors incorporating 2A linker peptides, the expression of both the and chains is mediated by the vector LTR gene promoter through an open reading frame, and 'cleavage' of the -and chains is accomplished at the protein level, where incomplete peptide bond formation between two components in the linker peptide design results in two separate proteins. MSGV1-1G4-AGSGP2AB (GSGP2A) incorporates coding sequences generated from the porcine teschovirus-1 and includes a GSG (glycine-serine-glycine) 'spacer' sequence. MSGV1-1G4-AGSGT2AB (GSGT2A) incorporates coding sequences generated from the Thosea asigna virus and includes a GSG 'spacer' sequence. MSGV1-1G4-AT2AB (T2A) is essentially identical to MSGV1-1G4-AGSGT2AB with the exception that it lacks a GSG 'spacer' sequence. The MSGV1-Cys1G4-AfrnSGSGP2AB (CysfrnSGSGP2A) vector incorporates and chains of the 1G4 NY-ESO-1 TCR in which we replaced a Thr 48 on the chain and a Ser 57 on the chain with cysteines to facilitate the creation of an additional disulWde bond between the TCR constant regions in an eVort to enhance TCR stability lated into increased eVector function against melanoma targets, we next measured IFN-release following cultured of PBL with melanoma tumor cell lines. Antigen-speciWc IFN-release was detected in co-cultures of HLA-A2+, NY-ESO+ melanoma tumors with all TCR constructs, with a higher level of cytokine secretion for PBL transduced with the constructs incorporating the 2A linker peptides (Fig. 3b) . These Wndings were consistent in four independent experiments.
TCR expression and eVector function of PBL transduced with modiWed TCR vector
We previously demonstrated that supplement of an additional disulWde bond in the constant regions of the TCR results in improve pairing of and chains in the introduced TCR with increased surface expression and improved eVector function of PBL electroporated with the cysteine-modiWed TCR [30] . To test the hypothesis that incorporation of this cysteine-modiWed TCR into our vector constructs would enhance TCR expression beyond that seen with 2A linker peptides alone, we created a vector construct incorporating and chains for the 1G4 NY-ESO TCR in which we replaced Thr 48 on the chain and Ser 57 on the chain with cysteines to facilitate the creation of an additional interchain disulWde bond between the TCR constant regions, as had originally been described by Boulter et al. [31] .
A retroviral vector, MSGV1-Cys1G4-AfrnSGSGP2AB (CysfrnSGSGP2A), was constructed incorporating genes encoding the cysteine-modiWed and chains joined by a coding sequence for a 2A linker peptide (Fig. 1) . In this case, we incorporated a furin cleavage site at the 5Ј end of the linker to facilitate cleavage of the residual 2A peptide from the chain following translation. PBL were transduced with either the GSGP2A construct or the CysfrnSGSGP2A construct on day 2 post-stimulation. Five days following transduction, cells were harvested and stained for V 13.1, and NY-ESO-1 tetramer. Examples of transductions for GSGP2A and CysfrnSGSGP2A are shown in Fig. 4 . Transduction with constructs incorporating the cysteine-modiWed 1G4 TCR demonstrated a modest increase in expression of the TCR, both by V 13.1 staining and NY-ESO-1 tetramer (Fig. 4a) . There was also a slight increase in recognition of tumor targets in CysfrnSGSGP2A-transduced PBL that was consistent with our previous results (Fig. 4b) .
Induction of NY-ESO-1 expression by epigenetic modulation of target cells
We have previously shown that sequential treatment of tumor cells with the demethylating agent DAC and the histone deacetylase inhibitor DP resulted in induction of 
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untransduced GFP APB GSGP2A GSGT2A T2A T2A GSGT2A GSGP2A APB NY-ESO-1 expression in melanoma, lung, and esophageal cancer cell lines [23] . To test the extent to which NY-ESO-1 expression can be induced, a wider range of non-melanoma epithelial malignancies were treated with DAC, DP, or sequential DAC/DP. Each of the cell lines, with the exception of H1299, demonstrated little to no detectable expression of NY-ESO-1 in the basal state in culture with NM (Fig. 5) . Minimal induction of NY-ESO-1 expression was observed after 6-h exposure to DP at 25 ng/ml (a concentration approximately 1 log less than that observed in plasma at the maximum tolerated dose for this agent). Treatment of tumor lines with either DAC alone (0.1 mol/ l), or sequential DAC (0.1 mol/l)-DP (25 ng/ml) resulted in a signiWcant induction of NY-ESO-1 expression (Fig. 5) .
Recognition of tumor cell lines following epigenetic modulation
In our prior studies we demonstrated that the induction of NY-ESO-1 conferred recognition of treated tumor cell lines, but not normal human bronchial epithelial cells, by HLA-A2-restricted NY-ESO-1-speciWc CTLs [20] . The CTLs in our prior studies were generated by in vitro peptide stimulation of lymphocytes obtained from a patient with HLA-A2+ melanoma who had a high serum antibody titer against NY-ESO-1 [20] . We next sought to determine if the increased NY-ESO-1 expression in the treated tumor cell lines conferred recognition by NY-ESO-1 TCR-transduced PBL. Treated tumor lines were co-cultured with PBL transduced with the CysfrnSGSGP2A construct. Transduction eYciency was 60% by V 13.1 and 50% by NY-ESO-1 tetramer staining (data not shown).
All of the HLA-A2+ tumor cell lines treated with either DAC or sequential DAC-DP were recognized by the TCRtransduced PBL (Fig. 6) . To test whether the increased sensitivity observed following treatment of tumors with DAC or DAC-DP was due to up-regulation of MHC class I molecules, we assessed HLA class I expression in cultured cancer cells by FACS analysis of the W6/32 antibody that recognizes only functional class I molecules. We observed no signiWcant diVerence in expression of HLA class I by FACS analysis on tumor cells undergoing no treatment (NM), treatment with DAC, DP, or sequential DAC-DP (data not shown). The magnitude of the cytokine release corresponded with the mRNA copy number in the treated cells, which was consistent with Wndings from our prior studies [20] .
Discussion
T cell receptor-based genetic immunotherapy for cancer involves the transfer of genes encoding TCRs into PBL with the goal of conferring reactivity against tumor targets expressing the cognate antigen. This therapy is based on knowledge gained through the study of the adoptive transfer of TIL, which can result in objective tumor regression when transferred following a lymphodepleting conditioning regimen in patients with metastatic melanoma [1] . However, TIL therapy has several limitations. First, a tumor must be removed via a surgical procedure to procure TIL. Depending on the location of the tumor, there may be signiWcant associated morbidity and a prolonged recovery. Second, tumor-reactive cells must be isolated and expanded ex vivo, which is generally only successful in half of patients. Third, the process of ex vivo expansion takes up to 2 months, thus treatment may be delayed if reactive TIL cannot be generated. Furthermore, reactive TIL are diYcult to generate in histologies other than melanoma, thus cancer immunotherapy using this strategy may not be applicable in to other malignancies. In TCR-based genetic immunotherapy, TCRs targeting TAA are cloned and inserted into viral vectors. These vectors can then be used to transduce PBL to license them for antigen recognition and tumor destruction. We have recently developed retroviral vectors with TCR targeting several TAA, including those targeting the HLA-A2-restricted immunodominant epitopes of the MART-1 and gp100 antigens [2, 3] . We have employed TCR-transduced PBL in on-going clinical trials to treat patients with metastatic melanoma. Our early experience with this form of therapy yielded a low response rate (13% by RECIST criteria) [4] , however we have since made modiWcations to the TCR and vector constructs which has resulted in improved TCR avidity and tumor reactivity of transduced PBL in vitro [30, 32, 33] .
In addition to developing TCRs targeting melanoma antigens, we have generated TCRs targeting TAA expressed in a wide range of non-melanoma epithelial malignancies [5, 34, 35] . One of these TCR targets NY-ESO-1, a CT antigen that is expressed in approximately one-third of melanoma tumors as well as a wide range of other malignancies [6, 7] . Since development of the original anti-NY-ESO-1 TCR vector in 2005 [5] , we have made modiWcations to the TCR to increase its aYnity and antigen-speciWc recognition [29] . Furthermore, modiWcations utilizing targeted mutations in the CDR2 or CDR3 regions of TCR can signiWcantly enhance antigen-speciWc recognition, and confer this recognition to both CD4 and CD8+ T lymphocytes [36] .
Having isolated a high aYnity NY-ESO-1 speciWc TCR, we sought to optimize gene transfer vector design. The Wrst two TCR vector designs analyzed used either an IRES or internal promoter to express both TCR chains. While these designs had been highly successful with previous TCRs [2, 35] , the IRES proved to be ineVective in mediating TCR expression. While we have observed a lack of IRES vector activity with other TCRs, this is not a common Wnding.
The most active retroviral constructs used in this report incorporated coding sequences for 2A linker peptides between the and chains of the NY-ESO-1 TCR. T cells transduced with these vectors demonstrated signiWcantly enhanced TCR expression by FACS analysis and improved eVector function as measured by cytokine release following co-culture with peptide-pulsed target cells or tumor cells expressing the NY-ESO-1 antigen (Figs. 2, 3) . The improved TCR expression and eVector function following TCR transduction of PBL with these vector constructs has direct implications for future vector design for immunotherapy as well as other gene therapy trials. This design strategy may also allow incorporation of coding sequences for additional genes that may further enhance eVector function, such as cytokines and co-stimulatory molecules. We also conWrmed our previous Wndings that addition of cysteine modiWcations to TCRs results in improved expression in PBL, perhaps by facilitating pairing of the introduced and [30] . In addition to improving TCR avidity and improved TCR expression through vector design, we sought to enhance reactivity against tumor targets by increasing their level of antigen expression. This is based on evidence that widespread changes in DNA methylation status and chromatin structure occur during the process of carcinogenesis leading to changes in gene expression [37] , which include increased expression of the CT antigens [20] . We have demonstrated that expression of antigens such as NY-ESO-1 can be selectively up-regulated in tumor cells by treatment with demethylating agents and histone deacetylase inhibitors, and can sensitize them to recognition by CTLs speciWc for the antigen [20] . In a phase I clinical trial, we used these agents to treat patients with advanced malignancies, and were able to demonstrate up-regulation of NY-ESO-1, MAGE, or p16 in approximately one-third of evaluable patients [38] . In this trial, all of the 35 patients enrolled were evaluable for toxicity. The most common toxicities were hematologic, with grade 3 leukopenia occurring in 20 of 35, grade 3 thrombocytopenia in 2 of 35, and grade 3 anemia in 3 of 35 patients [38] . We also reported that treatment with these agents with resultant increased expression of NY-ESO-1 in human melanoma and non-melanoma cell lines and can sensitize them to recognition by CTLs speciWc for the antigen [20] . We have applied these Wndings in animal studies, in which systemic treatment with DAC resulted in improved responses to adoptive transfer of speciWc CTL targeting the P1A CT antigen in this model [39] , providing the basis for studying the cooperative eVects of treatment with these agents in conjunction with adoptive immunotherapy. Taken together, these data demonstrate that treatment of target cells with demethylating agents alone or in combination with a histone deacetylase inhibitor causes up-regulation of CT antigen expression which confers recognition of these tumor targets to HLA-restricted, TCR-transduced PBL. These Wndings have signiWcant implications as we move forward with TCR-based genetic immunotherapy for melanoma as well as non-melanoma epithelial malignancies, and suggest that a combination of immunotherapy and epigenetic modulation may be a useful clinical strategy. Incorporation of pre-treatment with chromatin-remodeling agents followed by adoptive transfer of TCR-transduced PBL targeting CT antigens may provide a therapeutic beneWt over TCR-based immunotherapy alone.
